GlassScriptPhysician profile
Katy Flowers
NPI 1194274878
$9,111.17
in general payments reported to CMS, 2019-2025
36 companies · $1,624 in 2025
The $1,624 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,896 · 2022: $1,928 · 2023: $1,700 · 2024: $1,963 · 2025: $1,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,275 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,275.17 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,253.17 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,163.44 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,005.22 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $869.10 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $632.33 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $606.73 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $590.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.18 | 2021-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $385.82 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $342.58 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $246.24 | 2023-2025 | Caplyta |
| Corcept Therapeutics | $220.63 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $189.70 | 2021-2023 | Verquvo, Belsomra, Lagevrio |
| Axsome Therapeutics, INC. | $181.00 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $125.54 | 2021-2024 | Xarelto |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $119.21 | 2024-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $103.03 | 2022-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $96.44 | 2021-2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $77.76 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $49.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $42.24 | 2021 | |
| Sumitomo Pharma America, INC. | $37.22 | 2025 | Gemtesa |
| Acadia Pharmaceuticals INC | $34.23 | 2022 | |
| Lundbeck LLC | $30.82 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $29.46 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $27.26 | 2025 | Xhance, Nuzyra |
| Philips North America LLC | $19.30 | 2024 | (Ck7) Extended Holter |
| Eisai INC. | $17.76 | 2021 | |
| Boston Scientific Corporation | $16.93 | 2025 | Watchman Access System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.79 | 2023 | Xifaxan |
| Vanda Pharmaceuticals INC. | $16.62 | 2024 | Fanapt, Hetlioz |
| Phadia US INC. | $15.52 | 2025 | Immunocap |
| Viatris Specialty LLC | $14.53 | 2025 | Yupelri |
| Dexcom, INC. | $12.94 | 2021 | |
| Rhythm Pharmaceuticals, INC. | $12.67 | 2021 | |
| Mylan Specialty L.P. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Flowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.